UNSPSC 51284129: Cefetamet pivoxil hydrochloride

This classification denotes a cephalosporin antibiotic C20H25N5O7S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2YE9732GFU, chemically known as (6r,7r)-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester hydrochloride, but more generally known as cefetamet pivoxil hydrochloride, which bears US NIH Compound Identifier 5485221.

UNSPSC 51284129 Cefetamet pivoxil hydrochloride is a Commodity code that nominally describes a specific antimicrobial pharmaceutical compound, but recent state and local procurement activity under this code does not reflect purchases of cefetamet pivoxil itself. Instead, the code appears to be used in broader pharmaceutical and medical supply solicitations where state and local health agencies, fire departments, and cooperative purchasing organizations source generic pharmaceuticals, over-the-counter products, emergency medical supplies, and pharmacy benefit program components. The issuing bodies span state health and human services departments, county health departments, municipal fire departments, and multistate cooperative purchasing alliances. Work being solicited includes contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers, direct-to-manufacturer prescription programs, emergency medical and first aid supplies for rescue operations, and naloxone and drug deactivation systems for community health initiatives.

Recent opportunities include the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026), the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000.00 (due March 13, 2026), Seminole County, Florida's IFB for naloxone and safe drug deactivation systems—1,900 units of naloxone and 800 deactivation systems annually (due July 26, 2023), and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription program capabilities (due April 3, 2026). Geographic activity centers on Minnesota through MMCAP's multistate cooperative (which includes Oregon as a participating entity), Florida, Texas, and the Tampa Bay region. The code shows activity across state procurement offices, county health departments, and municipal purchasing departments, with cooperative purchasing vehicles driving broader regional participation and standardized contracting terms.